What Are The Drawbacks Of Current Front-Line Drugs to Treat C. difficile Infection?
JUN 09, 2017 | CONTAGION® EDITORIAL STAFF
Kirk Hevener, PharmD, PhD, Assistant Professor, Pharmaceutical Sciences, University of Tennessee Health Science Center, explains the drawbacks of first-line drugs that are currently used to treat C. difficile infections.
Interview Transcript (slightly modified for readability)
“The first-line agents that are currently used to treat [Clostridium] C. difficile infection, are metronidazole and another agent called vancomycin. We have been using these agents for several decades now to treat this particular infection, and they do have some drawbacks that are actually very important to know.
The first is that they’re relatively broad-spectrum antibacterials, and that’s important with C. difficile infection because, C. difficile infection is actually associated with the use of broad-spectrum antibacterials. So, essentially what we’re doing, is we’re treating an infection that was brought about by the use of broad-spectrum antibacterials, with broad-spectrum antibacterials, which can cause what we call ‘recurrence’ of CDI infection.
The reason this is important is because when we use these broad-spectrum antibacterials, metronidazole and vancomycin, patients can have what we call a recurrence: the infection can come back. Even though it looks cured, they can recur with the infection. What that means is they have a higher incidence of mortality and morbidity with recurrence—second, third, or even fourth recurrences have significantly increased rates of mortality.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512